Clinical Trials
23 trialsNCT03279692 2026-01-29
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT02648997 2026-01-26
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03095248 2025-04-22
SEL-TH-1601
Children's Hospital Medical Center, Cincinnati
Phase 2 Terminated
NCT03016091 2025-02-18
A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
Rabin Medical Center
Phase 2 Terminated
NCT00895622 2023-09-08
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
Radiation Therapy Oncology Group
Phase 2 Completed
NCT03273712 2023-02-09
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
University of Iowa
Phase 2 Completed
NCT02831257 2022-06-13
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Massachusetts General Hospital
Phase 2 Completed
NCT00972335 2021-11-10
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT01032200 2021-09-28
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
Wake Forest University Health Sciences
Phase 2 Completed
NCT01967823 2021-03-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01125046 2021-01-22
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Phase 2 Completed
NCT01966809 2019-08-20
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Medical College of Wisconsin
Phase 2 Terminated
NCT00348790 2018-10-26
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Northwestern University
Phase 2 Completed
NCT00859040 2017-10-27
Monthly SOM230C for Recurrent or Progressive Meningioma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00003483 2017-08-24
Antineoplaston Therapy in Treating Patients With Meningioma
Burzynski Research Institute
Phase 2 Terminated
NCT01419639 2017-07-18
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
NYU Langone Health
Phase 2 Completed
NCT00045734 2017-05-15
Imatinib Mesylate in Treating Patients With Recurrent Meningioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00706810 2017-04-13
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
University of Utah
Phase 2 Completed
NCT00003590 2016-05-20
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
SWOG Cancer Research Network
Phase 2 Completed
NCT00589784 2016-01-25
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00813592 2014-06-11
Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma
University of Utah
Phase 2 Terminated
NCT00492089 2014-05-09
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00354913 2013-01-18
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Duke University
Phase 2 Completed